Shearman & Sterling Advises Credit Suisse, BofA Securities, SVB Securities And Van Lanschot Kempen In European Biotech Acquisition Corp.’S Business Combination With Oculis SA
A&O Shearman was formed in 2024 via the merger of two historic firms, Allen & Overy and Shearman & Sterling. With nearly 4,000 lawyers globally, we are equally fluent in English law, U.S. law and the laws of the world’s most dynamic markets.
This combination creates a new kind of law firm, one built to achieve unparalleled outcomes for our clients on their most complex, multijurisdictional matters – everywhere in the world. A firm that advises at the forefront of the forces changing the current of global business and that is unrivalled in its global strength.
Our clients benefit from the collective experience of teams who work with many of the world’s most influential companies and institutions, and have a history of precedent-setting innovations.
Together our lawyers advise more than a third of NYSE-listed businesses, a fifth of the NASDAQ and a notable proportion of the London Stock Exchange, the Euronext, Euronext Paris and the Tokyo and Hong Kong Stock Exchanges.
Shearman & Sterling advised Credit Suisse, BofA Securities, SVB Securities and Van Lanschot Kempen acting as private placement agents in the business combination and $91 million...
United States
Shearman & Sterling advised Credit Suisse, BofA Securities,
SVB Securities and Van Lanschot Kempen acting as private placement
agents in the business combination and $91 million PIPE transaction
between European Biotech Acquisition Corp. and Oculis SA.
The transaction was announced on Nov. 7, 2022 and closed on
March 3, 2023. The shares and warrants began trading on the Nasdaq
under the ticker symbols "OCS" and "OCSAW",
respectively, on March 3. At closing, Oculis had a pro-forma
enterprise value of approximately $220 million and a cash balance
exceeding $109 million.
Credit Suisse, BofA Securities, SVB Securities, Van Lanschot
Kempen and Arctica Finance acted as joint private placement agents
for the business combination.
Oculis is a clinical-stage biopharmaceutical company, based in
Switzerland, with substantial expertise in therapeutics used to
treat ocular diseases. European Biotech Acquisition Corp. is a
special purpose acquisition company sponsored by an affiliate of
Life Sciences Partners.
Contributor
A&O Shearman was formed in 2024 via the merger of two historic firms, Allen & Overy and Shearman & Sterling. With nearly 4,000 lawyers globally, we are equally fluent in English law, U.S. law and the laws of the world’s most dynamic markets.
This combination creates a new kind of law firm, one built to achieve unparalleled outcomes for our clients on their most complex, multijurisdictional matters – everywhere in the world. A firm that advises at the forefront of the forces changing the current of global business and that is unrivalled in its global strength.
Our clients benefit from the collective experience of teams who work with many of the world’s most influential companies and institutions, and have a history of precedent-setting innovations.
Together our lawyers advise more than a third of NYSE-listed businesses, a fifth of the NASDAQ and a notable proportion of the London Stock Exchange, the Euronext, Euronext Paris and the Tokyo and Hong Kong Stock Exchanges.
